Effect of CYP2D6*4 , CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma.
Larisa K MoshetovaMaria M SoshinaKsenia I TurkinaElena A GrishinaZhannet Alimovna SozaevaAnastasiya A KachanovaKristina Anatolyevna AkmalovaDmitriy V IvashchenkoMikhail S ZastrozhinVladimir P FisenkoDmitry Alekseevich SychevPublished in: Drug metabolism and personalized therapy (2022)
gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timolol maleate in patients with POAG.